Sotatercept for the Treatment of Pulmonary Arterial Hypertension

• Published in: The New England journal of medicine Vol. 384; no. 13; pp. 1204 - 1215
• Main Authors: Humbert, Marc, McLaughlin, Vallerie, Gibbs, J. Simon R, Gomberg-Maitland, Mardi, Hoeper, Marius M, Preston, Ioana R, Souza, Rogerio, Waxman, Aaron, Escribano Subias, Pilar, Feldman, Jeremy, Meyer, Gisela, Montani, David, Olsson, Karen M, Manimaran, Solaiappan, Barnes, Jennifer, Linde, Peter G, de Oliveira Pena, Janethe, Badesch, David B
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 01.04.2021
• Subjects: Adult; Adverse events; Body weight; Brain natriuretic peptide; Cardiology and cardiovascular system; Confidence intervals; Dose-Response Relationship; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Tolerance; Exercise Tolerance - drug effects; Female; Fusion protein; Hemoglobin; Human health and pathology; Humans; Hypertension; Injections; Injections, Subcutaneous; International organizations; Intubation; Laboratories; Least-Square Analysis; Least-Squares Analysis; Life Sciences; Long bone; Male; Middle Aged; Mutation; Natriuretic Peptide; Natriuretic Peptide, Brain - blood; Peptide Fragments; Peptide Fragments - blood; Pharmaceutical sciences; Pharmacology; Placebos; Pulmonary Arterial Hypertension; Pulmonary Arterial Hypertension - blood; Pulmonary Arterial Hypertension - drug therapy; Pulmonary Arterial Hypertension - physiopathology; Pulmonary arteries; Pulmonary hypertension; Pulmonology and respiratory tract; Recombinant Fusion Proteins; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - pharmacology; Recombinant Fusion Proteins - therapeutic use; School dropouts; Signal transduction; Statistical analysis; Thrombocytopenia; Thrombocytopenia - chemically induced; Transforming Growth Factor beta; Transforming Growth Factor beta - antagonists & inhibitors; Vascular Resistance; Vascular Resistance - drug effects; Veins & arteries; Walk Test

Patients with pulmonary arterial hypertension were randomly assigned to receive sotatercept at a dose of 0.3 mg per kilogram or 0.7 mg per kilogram or placebo, in addition to standard therapy. At 24 weeks, both sotatercept groups had a greater reduction in pulmonary vascular resistance than the plac...